Search results
Results from the WOW.Com Content Network
The national vaccination program started including the pneumococcal vaccine for newborns in April 2006. [19] The Health Council advised in 2018 that those who are over the age of 60 should also be vaccinated on a 5-year recurring schedule. The resulting program from this, NPPV, started at the end of 2020. [20]
Prevnar vaccine. Prevnar 20 (PCV20) is the third version of a vaccine produced by the Wyeth subsidiary of Pfizer.In April 2023, the FDA approved Prevnar 20 for the prevention of invasive disease caused by the 20 different serotypes of S. pneumoniae contained in the vaccine (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F) for individuals 6 ...
The pneumococcal polysaccharide vaccine is widely used in high-risk adults. [4] First used in 1945, the tetravalent vaccine was not widely distributed, since its deployment coincided with the discovery of penicillin. [5] In the 1970s, Robert Austrian championed the manufacture and distribution of a 14-valent pneumococcal polysaccharide vaccine.
Doctors have long urged people ages 50 and older to get a shot to protect against bacterial pneumonia.
Merck's vaccine, branded Capvaxive, helped produce an immune response against all 21 serotypes, or variations of the bacteria, that the shot targeted in a variety of adult populations across studies.
Vancomycin is a glycopeptide antibiotic medication used to treat certain bacterial infections. [7] It is administered intravenously (injection into a vein) to treat complicated skin infections, bloodstream infections, endocarditis, bone and joint infections, and meningitis caused by methicillin-resistant Staphylococcus aureus. [8]
It is the most common bacterial pneumonia found in adults, the most common type of community-acquired pneumonia, and one of the common types of pneumococcal infection. The estimated number of Americans with pneumococcal pneumonia is 900,000 annually, with almost 400,000 cases hospitalized and fatalities accounting for 5-7% of these cases. [2]
There are also strains of enterococci that have developed resistance to vancomycin referred to as vancomycin resistant enterococcus (VRE). Agents classified as fourth-line (or greater) treatments or experimental therapies could be considered by default to be drugs of last resort due to their low placement in the treatment hierarchy.